Skip to main content
Top
Published in: European Journal of Medical Research 1/2013

Open Access 01-12-2013 | Research

Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods

Authors: Lingyan Zhang, Ying Guo, Bibo Li, Juan Qu, Chunbao Zang, Fang Li, Ying Wang, Hua Pang, Shaolin Li, Qingjun Liu

Published in: European Journal of Medical Research | Issue 1/2013

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide. Despite several efforts to elucidate molecular mechanisms involved in this cancer, they are still not fully understood.

Methods

To acquire further insights into the molecular mechanisms of HCC, and to identify biomarkers for early diagnosis of HCC, we downloaded the gene expression profile on HCC with non-cancerous liver controls from the Gene Expression Omnibus (GEO) and analyzed these data using a combined bioinformatics approach.

Results

The dysregulated pathways and protein-protein interaction (PPI) network, including hub nodes that distinguished HCCs from non-cancerous liver controls, were identified. In total, 29 phenotype-related differentially expressed genes were included in the PPI network. Hierarchical clustering showed that the gene expression profile of these 29 genes was able to differentiate HCC samples from non-cancerous liver samples. Among these genes, CDC2 (Cell division control protein 2 homolo g), MMP 2 (matrix metalloproteinase-2) and DCN (Decorin were the hub nodes in the PPI network.

Conclusions

This study provides a portfolio of targets useful for future investigation. However, experimental studies should be conducted to verify our findings.
Appendix
Available only for authorised users
Literature
1.
go back to reference El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132: 2557–2576. 10.1053/j.gastro.2007.04.061CrossRefPubMed El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132: 2557–2576. 10.1053/j.gastro.2007.04.061CrossRefPubMed
2.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61: 69–90. 10.3322/caac.20107CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61: 69–90. 10.3322/caac.20107CrossRefPubMed
3.
go back to reference Avila MA, Berasain C, Sangro B, Prieto J: New therapies for hepatocellular carcinoma. Oncogene 2006, 25: 3866–3884. 10.1038/sj.onc.1209550CrossRefPubMed Avila MA, Berasain C, Sangro B, Prieto J: New therapies for hepatocellular carcinoma. Oncogene 2006, 25: 3866–3884. 10.1038/sj.onc.1209550CrossRefPubMed
4.
go back to reference Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127: S5-S16. 10.1053/j.gastro.2004.09.011CrossRefPubMed Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127: S5-S16. 10.1053/j.gastro.2004.09.011CrossRefPubMed
5.
go back to reference El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340: 745–750. 10.1056/NEJM199903113401001CrossRefPubMed El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340: 745–750. 10.1056/NEJM199903113401001CrossRefPubMed
6.
go back to reference Harnois DM: Hepatitis C virus infection and the rising incidence of hepatocellular carcinoma. Mayo Clin Proc 2012, 87: 7–8. 10.1016/j.mayocp.2011.11.004PubMedCentralCrossRefPubMed Harnois DM: Hepatitis C virus infection and the rising incidence of hepatocellular carcinoma. Mayo Clin Proc 2012, 87: 7–8. 10.1016/j.mayocp.2011.11.004PubMedCentralCrossRefPubMed
7.
go back to reference Hassan MM, Frome A, Patt YZ, El-Serag HB: Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002, 35: 266–269. 10.1097/00004836-200209000-00013CrossRefPubMed Hassan MM, Frome A, Patt YZ, El-Serag HB: Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002, 35: 266–269. 10.1097/00004836-200209000-00013CrossRefPubMed
8.
go back to reference Soini Y, Chia SC, Bennett WP, Groopman JD, Wang JS, DeBenedetti VM, Cawley H, Welsh JA, Hansen C, Bergasa NV, et al.: An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 1996, 17: 1007–1012. 10.1093/carcin/17.5.1007CrossRefPubMed Soini Y, Chia SC, Bennett WP, Groopman JD, Wang JS, DeBenedetti VM, Cawley H, Welsh JA, Hansen C, Bergasa NV, et al.: An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 1996, 17: 1007–1012. 10.1093/carcin/17.5.1007CrossRefPubMed
10.
go back to reference Blum HE: Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005, 11: 7391–7400.PubMed Blum HE: Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005, 11: 7391–7400.PubMed
11.
go back to reference Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19: 271–285. 10.1055/s-2007-1007117CrossRefPubMed Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19: 271–285. 10.1055/s-2007-1007117CrossRefPubMed
12.
go back to reference Lee MJ, Yu GR, Park SH, Cho BH, Ahn JS, Park HJ, Song EY, Kim DG: Identification of cystatin B as a potential serum marker in hepatocellular carcinoma. Clin Cancer Res 2008, 14: 1080–1089. 10.1158/1078-0432.CCR-07-1615CrossRefPubMed Lee MJ, Yu GR, Park SH, Cho BH, Ahn JS, Park HJ, Song EY, Kim DG: Identification of cystatin B as a potential serum marker in hepatocellular carcinoma. Clin Cancer Res 2008, 14: 1080–1089. 10.1158/1078-0432.CCR-07-1615CrossRefPubMed
13.
go back to reference Marrero JA, Lok AS: Newer markers for hepatocellular carcinoma. Gastroenterology 2004, 127: S113-S119. 10.1053/j.gastro.2004.09.024CrossRefPubMed Marrero JA, Lok AS: Newer markers for hepatocellular carcinoma. Gastroenterology 2004, 127: S113-S119. 10.1053/j.gastro.2004.09.024CrossRefPubMed
14.
go back to reference Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125: 89–97. 10.1016/S0016-5085(03)00689-9CrossRefPubMed Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125: 89–97. 10.1016/S0016-5085(03)00689-9CrossRefPubMed
15.
go back to reference Daduang J, Limpaiboon T, Daduang S: Biomarker to distinguish hepatocellular carcinoma from cholangiocarcinoma by serum a disintegrin and metalloprotease 12. Arch Med Sci 2011, 7: 1013–1016.PubMedCentralCrossRefPubMed Daduang J, Limpaiboon T, Daduang S: Biomarker to distinguish hepatocellular carcinoma from cholangiocarcinoma by serum a disintegrin and metalloprotease 12. Arch Med Sci 2011, 7: 1013–1016.PubMedCentralCrossRefPubMed
16.
go back to reference Smith MW, Yue ZN, Geiss GK, Sadovnikova NY, Carter VS, Boix L, Lazaro CA, Rosenberg GB, Bumgarner RE, Fausto N, et al.: Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res 2003, 63: 859–864.PubMed Smith MW, Yue ZN, Geiss GK, Sadovnikova NY, Carter VS, Boix L, Lazaro CA, Rosenberg GB, Bumgarner RE, Fausto N, et al.: Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res 2003, 63: 859–864.PubMed
17.
go back to reference Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, Hirohashi S: Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003, 37: 198–207. 10.1053/jhep.2003.50022CrossRefPubMed Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, Hirohashi S: Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003, 37: 198–207. 10.1053/jhep.2003.50022CrossRefPubMed
18.
go back to reference Deng YB, Nagae G, Midorikawa Y, Yagi K, Tsutsumi S, Yamamoto S, Hasegawa K, Kokudo N, Aburatani H, Kaneda A: Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. Cancer Sci 2010, 101: 1501–1510. 10.1111/j.1349-7006.2010.01549.xCrossRefPubMed Deng YB, Nagae G, Midorikawa Y, Yagi K, Tsutsumi S, Yamamoto S, Hasegawa K, Kokudo N, Aburatani H, Kaneda A: Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. Cancer Sci 2010, 101: 1501–1510. 10.1111/j.1349-7006.2010.01549.xCrossRefPubMed
19.
go back to reference Mathivanan S, Periaswamy B, Gandhi TK, Kandasamy K, Suresh S, Mohmood R, Ramachandra YL, Pandey A: An evaluation of human protein-protein interaction data in the public domain. BMC Bioinforma 2006, 7(5):S19.CrossRef Mathivanan S, Periaswamy B, Gandhi TK, Kandasamy K, Suresh S, Mohmood R, Ramachandra YL, Pandey A: An evaluation of human protein-protein interaction data in the public domain. BMC Bioinforma 2006, 7(5):S19.CrossRef
20.
go back to reference Team RDC: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2011. Team RDC: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2011.
21.
go back to reference Gautier L, Cope L, Bolstad BM, Irizarry RA: affy–analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20: 307–315. 10.1093/bioinformatics/btg405CrossRefPubMed Gautier L, Cope L, Bolstad BM, Irizarry RA: affy–analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20: 307–315. 10.1093/bioinformatics/btg405CrossRefPubMed
22.
go back to reference Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98: 5116–5121. 10.1073/pnas.091062498PubMedCentralCrossRefPubMed Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98: 5116–5121. 10.1073/pnas.091062498PubMedCentralCrossRefPubMed
23.
go back to reference Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001, 125: 279–284. 10.1016/S0166-4328(01)00297-2CrossRefPubMed Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001, 125: 279–284. 10.1016/S0166-4328(01)00297-2CrossRefPubMed
24.
go back to reference Kanehisa M: The KEGG database. Novartis Found Symp 2002, 247: 91–101. discussion 101–103, 119–128, 244–152CrossRefPubMed Kanehisa M: The KEGG database. Novartis Found Symp 2002, 247: 91–101. discussion 101–103, 119–128, 244–152CrossRefPubMed
25.
go back to reference da Huang W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4: 44–57.CrossRefPubMed da Huang W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4: 44–57.CrossRefPubMed
26.
go back to reference Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13: 2498–2504. 10.1101/gr.1239303PubMedCentralCrossRefPubMed Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13: 2498–2504. 10.1101/gr.1239303PubMedCentralCrossRefPubMed
27.
go back to reference Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, et al.: Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci USA 2006, 103: 17402–17407. 10.1073/pnas.0608396103PubMedCentralCrossRefPubMed Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, et al.: Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci USA 2006, 103: 17402–17407. 10.1073/pnas.0608396103PubMedCentralCrossRefPubMed
28.
go back to reference Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N: Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 2000, 59: 68–74. 10.1159/000012140CrossRefPubMed Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N: Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 2000, 59: 68–74. 10.1159/000012140CrossRefPubMed
29.
go back to reference Li KK, Ng IO, Fan ST, Albrecht JH, Yamashita K, Poon RY: Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma. Liver 2002, 22: 259–268. 10.1046/j.0106-9543.2002.01629.xCrossRefPubMed Li KK, Ng IO, Fan ST, Albrecht JH, Yamashita K, Poon RY: Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma. Liver 2002, 22: 259–268. 10.1046/j.0106-9543.2002.01629.xCrossRefPubMed
30.
go back to reference Myatt SS, Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007, 7: 847–859. 10.1038/nrc2223CrossRefPubMed Myatt SS, Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007, 7: 847–859. 10.1038/nrc2223CrossRefPubMed
31.
go back to reference Xia L, Huang W, Tian D, Zhu H, Zhang Y, Hu H, Fan D, Nie Y, Wu K: Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J Hepatol 2012, 57: 600–612. 10.1016/j.jhep.2012.04.020CrossRefPubMed Xia L, Huang W, Tian D, Zhu H, Zhang Y, Hu H, Fan D, Nie Y, Wu K: Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J Hepatol 2012, 57: 600–612. 10.1016/j.jhep.2012.04.020CrossRefPubMed
32.
go back to reference Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, Koh J, Chan SL, Chan AT, Lai PB, et al.: TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 2009, 124: 644–652. 10.1002/ijc.23968CrossRefPubMed Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, Koh J, Chan SL, Chan AT, Lai PB, et al.: TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 2009, 124: 644–652. 10.1002/ijc.23968CrossRefPubMed
33.
go back to reference Crawley JJ, Furge K: Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data. Genome Biol 2002, 3: RESEARCH0075.PubMedCentralCrossRefPubMed Crawley JJ, Furge K: Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data. Genome Biol 2002, 3: RESEARCH0075.PubMedCentralCrossRefPubMed
34.
go back to reference Chua MS, Bernstein LR, Li R, So SK: Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res 2006, 26: 1739–1743.PubMed Chua MS, Bernstein LR, Li R, So SK: Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res 2006, 26: 1739–1743.PubMed
35.
go back to reference Ellerbroek SM, Stack MS: Membrane associated matrix metalloproteinases in metastasis. Bioessays 1999, 21: 940–949. 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.0.CO;2-JCrossRefPubMed Ellerbroek SM, Stack MS: Membrane associated matrix metalloproteinases in metastasis. Bioessays 1999, 21: 940–949. 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.0.CO;2-JCrossRefPubMed
36.
go back to reference Seiki M: The cell surface: the stage for matrix metalloproteinase regulation of migration. Curr Opin Cell Biol 2002, 14: 624–632. 10.1016/S0955-0674(02)00363-0CrossRefPubMed Seiki M: The cell surface: the stage for matrix metalloproteinase regulation of migration. Curr Opin Cell Biol 2002, 14: 624–632. 10.1016/S0955-0674(02)00363-0CrossRefPubMed
37.
go back to reference Maatta M, Soini Y, Liakka A, Autio-Harmainen H: Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 2000, 6: 2726–2734.PubMed Maatta M, Soini Y, Liakka A, Autio-Harmainen H: Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 2000, 6: 2726–2734.PubMed
38.
go back to reference Ogasawara S, Yano H, Momosaki S, Nishida N, Takemoto Y, Kojiro S, Kojiro M: Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues. Oncol Rep 2005, 13: 1043–1048.PubMed Ogasawara S, Yano H, Momosaki S, Nishida N, Takemoto Y, Kojiro S, Kojiro M: Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues. Oncol Rep 2005, 13: 1043–1048.PubMed
39.
go back to reference Musso O, Theret N, Campion JP, Turlin B, Milani S, Grappone C, Clement B: In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis. J Hepatol 1997, 26: 593–605. 10.1016/S0168-8278(97)80425-4CrossRefPubMed Musso O, Theret N, Campion JP, Turlin B, Milani S, Grappone C, Clement B: In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis. J Hepatol 1997, 26: 593–605. 10.1016/S0168-8278(97)80425-4CrossRefPubMed
40.
go back to reference Chen RX, Xia YH, Xue TC, Ye SL: Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression. Mol Biol Rep 2011, 38: 3671–3677. 10.1007/s11033-010-0481-8CrossRefPubMed Chen RX, Xia YH, Xue TC, Ye SL: Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression. Mol Biol Rep 2011, 38: 3671–3677. 10.1007/s11033-010-0481-8CrossRefPubMed
41.
go back to reference Xiang ZL, Zeng ZC, Tang ZY, Fan J, Sun HC, Tan YS: Expression of cytokeratin 19 and matrix metalloproteinase 2 predicts lymph node metastasis in hepatocellular carcinoma. Mol Biol Rep 2011, 38: 3531–3539. 10.1007/s11033-010-0463-xCrossRefPubMed Xiang ZL, Zeng ZC, Tang ZY, Fan J, Sun HC, Tan YS: Expression of cytokeratin 19 and matrix metalloproteinase 2 predicts lymph node metastasis in hepatocellular carcinoma. Mol Biol Rep 2011, 38: 3531–3539. 10.1007/s11033-010-0463-xCrossRefPubMed
42.
go back to reference Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O, Antonaci S: Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002, 97: 425–431. 10.1002/ijc.1635CrossRefPubMed Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O, Antonaci S: Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002, 97: 425–431. 10.1002/ijc.1635CrossRefPubMed
43.
go back to reference Theret N, Musso O, L'Helgoualc'h A, Campion JP, Clement B: Differential expression and origin of membrane-type 1 and 2 matrix metalloproteinases (MT-MMPs) in association with MMP2 activation in injured human livers. Am J Pathol 1998, 153: 945–954. 10.1016/S0002-9440(10)65636-2PubMedCentralCrossRefPubMed Theret N, Musso O, L'Helgoualc'h A, Campion JP, Clement B: Differential expression and origin of membrane-type 1 and 2 matrix metalloproteinases (MT-MMPs) in association with MMP2 activation in injured human livers. Am J Pathol 1998, 153: 945–954. 10.1016/S0002-9440(10)65636-2PubMedCentralCrossRefPubMed
44.
go back to reference Poon RT, Chung KK, Cheung ST, Lau CP, Tong SW, Leung KL, Yu WC, Tuszynski GP, Fan ST: Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 2004, 10: 4150–4157. 10.1158/1078-0432.CCR-03-0435CrossRefPubMed Poon RT, Chung KK, Cheung ST, Lau CP, Tong SW, Leung KL, Yu WC, Tuszynski GP, Fan ST: Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 2004, 10: 4150–4157. 10.1158/1078-0432.CCR-03-0435CrossRefPubMed
45.
go back to reference Yumoto E, Nakatsukasa H, Hanafusa T, Yumoto Y, Nouso K, Matsumoto E, Onishi T, Takuma Y, Tanaka H, Fujikawa T, et al.: IGFBP-3 expression in hepatocellular carcinoma involves abnormalities in TGF-beta and/or Rb signaling pathways. Int J Oncol 2005, 27: 1223–1230.PubMed Yumoto E, Nakatsukasa H, Hanafusa T, Yumoto Y, Nouso K, Matsumoto E, Onishi T, Takuma Y, Tanaka H, Fujikawa T, et al.: IGFBP-3 expression in hepatocellular carcinoma involves abnormalities in TGF-beta and/or Rb signaling pathways. Int J Oncol 2005, 27: 1223–1230.PubMed
46.
go back to reference Gebhardt C, Nemeth J, Angel P, Hess J: S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006, 72: 1622–1631. 10.1016/j.bcp.2006.05.017CrossRefPubMed Gebhardt C, Nemeth J, Angel P, Hess J: S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006, 72: 1622–1631. 10.1016/j.bcp.2006.05.017CrossRefPubMed
47.
go back to reference Nemeth J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, Breuhahn K, Gebhardt C, Schirmacher P, Hahn M, et al.: S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology 2009, 50: 1251–1262. 10.1002/hep.23099CrossRefPubMed Nemeth J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, Breuhahn K, Gebhardt C, Schirmacher P, Hahn M, et al.: S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology 2009, 50: 1251–1262. 10.1002/hep.23099CrossRefPubMed
Metadata
Title
Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods
Authors
Lingyan Zhang
Ying Guo
Bibo Li
Juan Qu
Chunbao Zang
Fang Li
Ying Wang
Hua Pang
Shaolin Li
Qingjun Liu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2013
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/2047-783X-18-35

Other articles of this Issue 1/2013

European Journal of Medical Research 1/2013 Go to the issue